中国病毒性肝炎疾病负担研究进展

李健; 王富珍; 陈仲丹; 齐金蕾; 王爱玲; 赵方辉; 孔媛媛; 孙静; 康家琦; 尹遵栋; 刘中夫; 贾继东; 王宇

doi:10.12449/JCH250205

中国病毒性肝炎疾病负担研究进展

DOI: 10.12449/JCH250205

李健¹,
王富珍²,
陈仲丹³,
齐金蕾⁴,
王爱玲⁵,
赵方辉⁶,
孔媛媛⁷,
孙静⁸,
康家琦⁹,
尹遵栋²,
刘中夫¹,
贾继东⁷,
王宇^9, , ,

1.
中国疾病预防控制中心性病艾滋病预防控制中心，北京 102206
2.
中国疾病预防控制中心免疫规划中心，北京 100050
3.
世界卫生组织驻华代表处，北京 100600
4.
中国疾病预防控制中心慢性非传染性疾病预防控制中心，北京 100050
5.
国家卫生健康委妇幼健康中心，北京 100081
6.
国家癌症中心/中国医学科学院肿瘤医院，北京 100021
7.
首都医科大学附属北京友谊医院肝病中心，北京 100050
8.
北京协和医学院卫生健康管理政策学院，北京 100730
9.
中国肝炎防治基金会，北京 100106

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王宇、陈仲丹负责设计论文框架；李健、王富珍负责拟定写作思路并起草撰写论文；齐金蕾、王爱玲、赵方辉、孔媛媛、孙静、康家琦、尹遵栋、刘中夫、贾继东负责检索和收集相关材料并对论文进行修改；王宇负责指导撰写文章并最后定稿。

详细信息

通信作者:
王宇， wangyu@chinacdc.cn （ORCID： 0000-0002-7891-4633）

计量
- 文章访问数: 1259
- HTML全文浏览量: 74
- PDF下载量: 76
- 被引次数: 0
出版历程
- 收稿日期: 2024-11-30
- 录用日期: 2025-01-13
- 出版日期: 2025-02-25

Research advances in the disease burden of viral hepatitis in China

1.
National Center for AIDS/STD Control and Prevention，Chinese Center for Disease Control and Prevention，Beijing 102206，China
2.
National Immunization Program，Chinese Center for Disease Control and Prevention，Beijing 100050，China
3.
Technical Office，WHO China Office，Beijing 100600，China
4.
National Center for Chronic and Noncommunicable Disease Control and Prevention，Chinese Center for Disease Control and Prevention，Beijing 100050，China
5.
Maternal and Child Health Center，National Health Commission，Beijing 100081，China
6.
National Cancer Center/Cancer Hospital，Chinese Academy of Medical Sciences，Beijing 100021，China
7.
Liver Research Center，Beijing Friendship Hospital，Capital Medical University，Beijing 100050，China
8.
School of Health Management and Policy，Peking Union Medical College，Beijing 100730，China
9.
Chinese Foundation for Hepatitis Prevention and Treatment，Beijing 100106，China

More Information

Corresponding author: WANG Yu， wangyu@chinacdc.cn （ORCID： 0000-0002-7891-4633）

摘要

摘要: 在过去的30年，中国在病毒性肝炎防控领域取得显著成效，儿童新发HBV感染率、人群急性病毒性肝炎发病率均降至较低水平，但是中国慢性病毒性肝炎疾病负担仍然沉重，严重影响人群健康。本研究系统分析了中国病毒性肝炎预防控制所取得的工作成效，剖析目前存在的主要问题和挑战，结合中国国情，提出消除病毒性肝炎公共卫生危害的综合防控策略和措施，以期为助力推动中国相关部门就如何实现2030年消除病毒性肝炎公共卫生危害行动目标提供参考依据。
- 病毒性肝炎 /
- 患病代价 /
- 疾病消除
Abstract: Over the past three decades， China has made significant progress in the prevention and control of viral hepatitis， and the incidence rates of new-onset pediatric hepatitis B virus infections and acute viral hepatitis in the population have reduced to a relatively low level； however， there is still a heavy disease burden of chronic viral hepatitis in China， which severely affects the health status of the population. This study systematically summarizes the achievements of viral hepatitis prevention and control in China， analyzes existing problems and challenges， and proposes comprehensive prevention and control strategies and measures to eliminate viral hepatitis as a public health threat based on the national conditions of China， in order to provide a reference for related departments in China on how to achieve the action targets for eliminating viral hepatitis as a public health threat by 2030.
- Viral Hepatitis /
- Cost of Illness /
- Disease Eradication

HTML全文

图 1 1992—2020年中国4次病毒性肝炎血清流行病学调查人群分年龄HBsAg流行率^［10］

Figure 1. Age specific HBsAg prevalence in China with confidence intervals， China， 1992—2020^［10］

下载: 全尺寸图片幻灯片

注： a，采购量变化情况；b，费用支出情况。

图 2 国家药品集中采购政策实施两年后中国乙型肝炎抗病毒药物的采购量和费用支出情况^［11］

Figure 2. Quarterly change of volume and expenditures of HBV-related NAs from Apr 2018 to Feb 2021^［11］

下载: 全尺寸图片幻灯片

图 3 2020年中国病毒性肝炎血清流行病学调查HBsAg阳性者诊疗服务链^［10］

Figure 3. The health care cascade among HBsAg positive subjects， China， 2020^［10］

下载: 全尺寸图片幻灯片

图 4 2005—2020年中国分性别肝癌死亡数及标化死亡率

Figure 4. Sex-specific liver cancer deaths and standardized mortality in China， 2005—2020

下载: 全尺寸图片幻灯片

参考文献(25)

[1]	World Health Organization. Global health sector strategy on viral hepatitis 2016- 2021[EB/OL].( 2016-06)[ 2024-06-22]. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
[2]	National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, et al. Notice on the issuance of Action plan for the prevention and treatment of viral hepatitis in China by National Administration of Traditional Chinese Medicine(2017—2020)[J]. Gazette of the State Council of the People’s Republic of China, 2018,( 7): 76- 82. 国家计生卫生委, 国家发展改革委, 教育部, 等. 中医药局关于印发中国病毒性肝炎防治规划(2017-2020年)的通知[J]. 中华人民共和国国务院公报, 2018,( 7): 76- 82.
[3]	National Health Commission of the People’s Republic of China. Action plan for eliminating hepatitis C as a public health threat( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640 国家卫生健康委员会. 消除丙型肝炎公共卫生危害行动工作方案( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640
[4]	General Office of National Health and Family Planning Commission, General Office of Ministry of Finance. Notice on the implementation of nucleic acid testing in blood stations[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml 国家卫生计生委办公厅, 财政部办公厅. 关于做好血站核酸检测工作的通知[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml
[5]	XU JJ, HAN MJ, JIANG YJ, et al. Prevention and control of HIV/AIDS in China: Lessons from the past three decades[J]. Chin Med J(Engl), 2021, 134( 23): 2799- 2809. DOI: 10.1097/CM9.0000000000001842.
[6]	FU HC, XU J, ZHOU C, et al. Progress of community-based methadone maintenance treatment in China from 2004 to 2021[J]. Chin J AIDS STD, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06. 付鸿臣, 徐杰, 周楚, 等. 2004—2021年全国社区美沙酮维持治疗工作进展分析[J]. 中国艾滋病性病, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06.
[7]	TANG L, LIU QQ, WANG XQ, et al. Interrupted time series analyses of hepatitis A incidence in different endemic areas of China before and after introduction of hepatitis A vaccine into the national Expanded Program on Immunization[J]. Chin J Vaccines Immun, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005. 唐林, 刘倩倩, 王晓琪, 等. 中国扩大国家免疫规划前后不同流行区甲型肝炎报告发病率变化的中断时间序列分析[J]. 中国疫苗和免疫, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005.
[8]	Disease Prevention and Control Bureau, National Health Commission of the People’s Republic of China. An overview of national notifiable infectious diseases in 2021[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml 国家卫生健康委员会疾病预防控制局. 2021年全国法定传染病疫情概况[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml
[9]	WANG FZ, ZHENG H, SUN XJ, et al. Achievements and prospects for hepatitis B prevention and control in China[J]. Chin J Vaccines Immun, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001. 王富珍, 郑徽, 孙校金, 等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001.
[10]	ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
[11]	ZHAO XY, LI M, WANG H, et al. Impact of national centralized drug procurement policy on antiviral utilization and expenditure for hepatitis B in China[J]. J Clin Transl Hepatol, 2022, 10( 3): 420- 428. DOI: 10.14218/JCTH.2022.00167.
[12]	ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
[13]	HE J, CHEN WQ. China cancer registry annual report[M]. Beijing: People’s Medical Publishing House, 2018. 赫捷, 陈万青. 2017中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2018.
[14]	WANG SM, ZHENG RS, HAN BF, et al. Age distribution of cancer incidence and mortality in China in 2022[J]. China Cancer, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001. 王少明, 郑荣寿, 韩冰峰, 等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001.
[15]	WANG XX, LIU HX, QI JL, et al. Trends in mortality of cirrhosis in China: An analysis of the China death surveillance database from 2008 to 2020[J]. J Clin Transl Hepatol, 2024, 12( 3): 236- 244. DOI: 10.14218/JCTH.2023.00454.
[16]	ZHENG RS, CHEN R, HAN BF, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035. 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[17]	QI JL, LI ML, WANG LJ, et al. National and subnational trends in cancer burden in China, 2005-20: An analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8( 12): e943- e955. DOI: 10.1016/S2468-2667(23)00211-6.
[18]	LIU Y, ZHENG JX, HAO JL, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019[J]. Cancer Med, 2022, 11( 5): 1310- 1323. DOI: 10.1002/cam4.4551.
[19]	WANG X, LIN SX, TAO J, et al. Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol, 2014, 20( 37): 13546- 13555. DOI: 10.3748/wjg.v20.i37.13546.
[20]	WANG MJ, WANG YT, FENG XS, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15- 21. DOI: 10.1016/j.ijid.2017.09.003.
[21]	QIN SK. Interim report of China Liver Cancer Survey(CLCS)[C]. The 22nd National Congress of Clinical Oncology and 2019 CSCO Academic Conference, Xiamen, 2019. 秦叔逵. 中国原发性肝癌临床登记调查(CLCS)的中期报告[C]. 第22届全国临床肿瘤学大会暨2019年CSCO学术会议, 厦门, 2019.
[22]	National Health Commission of the People’s Republic of China. China Health Yearbook 2022[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf 国家卫生健康委员会. 2022中国卫生健康统计年鉴[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf
[23]	HAN MJ, CHEN QF, XU P, et al. Striving for the new journey of AIDS prevention and control during the 13th Five-Year Plan: Retrospects and prospects of AIDS prevention and control in China[J]. Chin J AIDS STD, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01. 韩孟杰, 陈清峰, 徐鹏, 等. 砥砺奋进“十三五”艾滋病防控迈向新征程: 我国艾滋病防治回顾与展望[J]. 中国艾滋病性病, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01.
[24]	XIAO HP. New advances in the prevention and treatment of tuberculosis[M]. Shanghai: Fudan University Press, 2004. 肖和平. 结核病防治新进展[M]. 上海: 复旦大学出版社, 2004.
[25]	World Health Organization. Global tuberculosis report 2020[EB/OL].( 2022-10-14)[ 2024-11-21]. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1